Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advance: MIN-102 in Adrenomyeloneuropathy
NCT03231878Phase 3Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Dec 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in adrenoleukodystrophy (ALD) comparing Leriglitazone with Placebo (2 arms). Primary endpoints: 6-Minute Walk Test Total Distance Walked at 240 weeks and Long-term Safety and Tolerability at 335 weeks. Started Dec 2017; status: completed.
02
Drugs
leriglitazone
03
Conditions
adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on NCT03231878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231878.